• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Khrom Capital Sends Letter to Board of Directors of Acadia Healthcare

    10/1/25 4:59:00 PM ET
    $ACHC
    Medical Specialities
    Health Care
    Get the next $ACHC alert in real time by email

    Acadia Healthcare Has Suffered Consistent Underperformance Under Current Leadership

    Believes Acadia Healthcare Should Launch a Formal Review of Strategic Alternatives to Maximize Value for Shareholders

    Khrom Capital Management LLC ("Khrom Capital"), which together with its investment funds and affiliates, owns 5.5% of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) ("Acadia" or the "Company") and is one of the Company's largest shareholders, today sent a letter to the Company's Board of Directors reiterating its belief that the Company should pursue a formal review of strategic alternatives, including a sale, in order to maximize value for its shareholders.

    The letter can be downloaded here.

    The full text of the letter is as follows:

    October 1, 2025

    Board of Directors

    Acadia Healthcare Company, Inc.

    6100 Tower Circle, Suite 1000

    Franklin, TN 37067

    Dear Members of the Board,

    We are one of Acadia Healthcare Company, Inc.'s ("Acadia" or the "Company") largest shareholders, currently owning over 5 million shares of the Company's common stock ("Shares"), representing approximately 5.5% of the Company. We have now written to you multiple times to express our deep concerns regarding Acadia's persistent underperformance, poor capital allocation, misaligned executive incentives, governance failures, and lack of accountability.

    Our private outreach has been met with nothing more than boilerplate responses—the same generic deflection that the Company issued in response to Engine Capital LP's September 24th letter. This is unacceptable. Shareholders deserve meaningful, urgent action to reverse Acadia's trajectory as one of the worst-performing healthcare stocks of the past decade as evidenced by Acadia's worst-in-class TSR.

    It is unfortunate that it has come to the point where we and other shareholders, such as Engine Capital, have had to step in to call out actions that Acadia's Board and management should have already been taking to enhance shareholder value. To be clear, we support the proposals outlined in Engine Capital's September 24th letter. These are steps that the Board and management should have already considered and implemented as part of their management of the Company. However, we believe that shareholder trust in this Board and management team has eroded to such an extent that incremental measures are no longer sufficient.

    We believe that the Board must immediately initiate a formal strategic review process, including the evaluation of a sale of all or part of the Company. Our research suggests that credible, interested bidders exist. Yet Acadia has refused to initiate a strategic review process. This refusal is troubling, and shareholders deserve a clear explanation for why the Board will not commence a strategic review process to determine whether it represents the best path to maximizing shareholder value.

    Of course, operational improvements—such as those proposed by Engine Capital—should continue in parallel. However, the Board's fiduciary obligations require that it consider and evaluate in good faith all avenues for value creation for its shareholders. We believe that the Board refusing to run a strategic review is, at best, negligent—and at worst, a breach of its fiduciary duties.

    Persistent Value Destruction

    Acadia's share price today is drastically lower than it was ten years ago. During this same period, peers such as HCA Healthcare, Inc., Universal Health Services, Inc., and Tenet Healthcare Corp. have created substantial value for their shareholders, while Acadia shareholders have suffered through what can only be called a "lost decade."

    Acadia Healthcare Total Shareholder Return Versus Peers
    Company TSR (YTD) TSR (1-Year) TSR (3-Year) TSR (5-Year) TSR (10-Year)
    Acadia Healthcare

    (44.5%)

    (71.1%)

    (71.7%)

    (20.1%)

    (70.7%)

    HCA Healthcare

    36.4%

    0.9%

    113.8%

    252.0%

    386.5%

    Tenet Healthcare

    53.0%

    14.9%

    265.1%

    787.3%

    334.5%

    Universal Health Services

    8.5%

    (19.1%)

    112.2%

    91.7%

    39.8%

    XHS (SPDR Healthcare Services)

    11.0%

    3.4%

    12.9%

    40.5%

    59.9%

    Russell 2000

    10.4%

    10.5%

    45.7%

    69.3%

    115.0%

    *Data as of 9/23/2025 close (prior to Engine Capital LP's letter)

    This underperformance is not the fault of industry dynamics. Rather, it is the direct result of repeated strategic missteps, entrenched and misaligned leadership, and a Board that has consistently refused to take responsibility for its actions.

    A Decade of Strategic Missteps

    For over ten years—with no meaningful Board refreshment—Acadia has made a series of costly errors, such as:

    • Entered and then exited the UK market.
    • Replaced proven CEO Debbie Osteen with leadership that has failed to generate value.
    • Launched another aggressive and poorly justified capital expenditure campaign.
    • Repurchased Shares and raised leverage amid a $1+ billion capex cycle, Department of Justice ("DOJ") investigation, civil lawsuits, and negative free cash flow.
    • Awarded executive bonuses simply for enduring the DOJ probe.

    These and other decisions have collectively destroyed shareholder value and eroded market trust, and the Board has taken no responsibility for these missteps. This is not an asset quality problem—it is a management and Board problem. The assets themselves remain valuable. What is broken is the governance and leadership structure that continues to make ill-advised decisions, entrench itself in power, and resist meaningful change.

    An Entrenched and Misaligned Board Has Destroyed Shareholder Value

    The Board has been content to collect compensation without adding value or refreshing its membership in the face of continued shareholder value destruction. The Board has failed to refresh itself despite prolonged underperformance:

    • Reeve B. Waud: 20 years
    • William F. Grieco: 14 years
    • Wade D. Miquelon: 13 years
    • E. Perot Bissell: 12 years
    • Vicky B. Gregg: 9 years
    • Jason R. Bernhard: 6 years
    • Michael J. Fucci: 5 years

    Compounding this problem, none of the directors own a material amount of Acadia stock. They lack any meaningful personal capital at risk, yet are making critical decisions about shareholder capital—decisions that have repeatedly destroyed value. A Board so financially misaligned with its owners cannot be trusted to act with the urgency and accountability that shareholders deserve.

    Governance Failures

    Acadia's governance structure has resulted in an entrenched Board that lacks accountability to its shareholders. We believe that the Company's stockholders deserve a Board whose interests are aligned with the Company's shareholders and that the following changes should be implemented to support such alignment:

    • Staggered Board. The Company's decision to wait until 2029 to de-stagger the Board is indefensible. Shareholders should not have to wait four more years for basic accountability. This timeline must be accelerated.
    • No Policy on Director Tenure. Several directors have served well over a decade—including Mr. Waud for 20 years—while presiding over chronic underperformance. Without meaningful refreshment, the Board is entrenched, stale, and resistant to change.
    • No Director Age Limits. Two current directors are in their 70s. Best-in-class boards enforce age limits to ensure continuous renewal and the regular infusion of fresh perspectives.
    • No Corporate Governance Guidelines. The Company lacks even the basic framework that most public companies adopt as a matter of course. A Code of Ethics is not a substitute for comprehensive corporate governance guidelines.
    • Lack Meaningful Ownership. Collectively, the Company's Board and management team, which according to the Company's 2025 proxy statement, includes 13 directors and executives, own only 1.3% of Acadia stock in the aggregate. With so little personal capital at risk, the Board and management team is alarmingly misaligned with its shareholders.
    • Shareholder Disenfranchisement. Only the Board—not shareholders—may call special meetings. This governance structure prioritizes entrenchment over accountability and demonstrates a clear disregard for shareholder rights.

    Together, these governance failures underscore why Acadia is seen as unresponsive, unaccountable, and incapable of creating value.

    Shareholders Have Lost Confidence

    Moreover, the Company's recent annual meeting results underscore this shareholder dissatisfaction. Significant votes "Against" the Company's nominees—3.3 million against Jason Bernhard, 8.8 million against William Grieco, 5.0 million against R. David Kelly, and a staggering 17.2 million against Reeve Waud—show an obvious lack of confidence and a desire for change among shareholders. These are not routine protest votes; they are a referendum on this Board's failure to create value.

    The Path Forward

    We support the growing chorus of shareholders calling for urgent and decisive action by Acadia's management and Board. This includes the proposals outlined by Engine Capital—such as enhancing governance, enforcing financial discipline, and pursuing asset sales. In parallel, however, the Board should immediately initiate a formal strategic review process to evaluate whether a partial or full sale of the Company would be the best path forward to maximize shareholder value. We believe that a full sale of the Company represents the most efficient and effective path to unlocking shareholder value and its consideration should be a top priority for this Board.

    There is no valid reason to delay or avoid conducting a competitive bidding process or evaluating serious offers from interested acquirers. Given the widespread erosion of confidence in this Board's leadership, the shareholders deserve a Board that will assess all credible alternatives.

    We believe that credible and interested parties are indeed out there. These opportunities must be surfaced through a formal, publicly announced strategic review process. Given Acadia's catastrophic share price performance, this Board's "wait and see" approach is no longer acceptable. A rigorous strategic review will demonstrate that the Board is finally willing to take meaningful, tangible steps to unlock value for the Company's owners.

    Importantly, the ongoing DOJ investigation cannot serve as an excuse for inaction. There is ample precedent for transactions being completed at attractive valuations during active regulatory reviews, including DOJ reviews. We are confident that the Company and potential acquirers would be able to negotiate terms that would provide adequate protection to an acquirer under these circumstances.

    The Board's fiduciary duty is to act in the best interests of all shareholders. If it refuses to do so, we—and, we believe, many other frustrated shareholders—will pursue all available avenues, including nominating directors and building broader shareholder support to enforce accountability.

    Conclusion

    We call on the Board to immediately:

    • Announce a good-faith, public strategic review process, including the evaluation of a potential sale of the Company.
    • Accelerate critical governance reforms, including de-staggering the Board well before 2029, implementing director age and tenure limits, and adopting comprehensive corporate governance guidelines.

    Excuses are no longer acceptable—meaningful action to create shareholder value must begin immediately.

    Sincerely,

    Eric Khrom

    Managing Partner

    Khrom Capital

    About Khrom Capital

    Khrom Capital Management, LLC manages approximately $1 billion of assets as of September, 30 2025. Founded in 2008, Khrom Capital is a North America–focused value-oriented fund.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251001386953/en/

    Linda Liu

    Head of Investor Relations

    Khrom Capital Management, LLC

    [email protected]

    Get the next $ACHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHC

    DatePrice TargetRatingAnalyst
    9/10/2025$25.00Buy → Neutral
    BofA Securities
    8/14/2025$26.00Strong Buy → Outperform
    Raymond James
    2/28/2025$43.00 → $35.00Overweight → Equal Weight
    Barclays
    1/7/2025$70.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2024$45.00 → $75.00Hold → Buy
    Deutsche Bank
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    4/25/2024$70.00Sell → Hold
    Deutsche Bank
    3/6/2024$100.00Overweight
    Barclays
    More analyst ratings

    $ACHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khrom Capital Sends Letter to Board of Directors of Acadia Healthcare

    Acadia Healthcare Has Suffered Consistent Underperformance Under Current Leadership Believes Acadia Healthcare Should Launch a Formal Review of Strategic Alternatives to Maximize Value for Shareholders Khrom Capital Management LLC ("Khrom Capital"), which together with its investment funds and affiliates, owns 5.5% of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) ("Acadia" or the "Company") and is one of the Company's largest shareholders, today sent a letter to the Company's Board of Directors reiterating its belief that the Company should pursue a formal review of strategic alternatives, including a sale, in order to maximize value for its shareholders. The letter can be downloaded

    10/1/25 4:59:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Issues Statement Highlighting Commitment to Value Creation

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today issued the following statement: Our Board of Directors and management team are steadfast in our commitment to enhancing long-term shareholder value. We regularly communicate with our shareholders regarding our value creation plan and welcome constructive input as we move forward. At Acadia, our mission is to create a world-class organization that sets the standard of excellence in the treatment of behavioral health and substance use disorders, and we are executing a focused strategy to position Acadia for the future. Our actions are centered on disciplined growth to expand access to high-quality behavioral healthcare, strengthening cli

    9/24/25 11:49:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Engine Capital Sends Letter to Acadia Healthcare's Board of Directors Regarding the Urgent Need for Strategy and Governance Changes

    Highlights That the Company Has Delivered Negative Returns and Underperformed Other Healthcare Facility Operators Over All Relevant Periods – Causing it to Trade at a Deep Discount to its Intrinsic Value Believes Acadia's Underperformance Stems from Poor Execution, a Flawed Reorganization Under CEO Christopher Hunter, Ballooning Costs, Poor Capital Allocation, and a Lack of Board Oversight Urges the Company to Immediately Halt Growth Capital Projects, Prioritize Operational and Cost Structure Improvements, Explore Potential Asset Sales, and Repurchase Undervalued Shares Makes Clear the Board Needs to Be Refreshed with New Directors Who Bring Behavioral Health Operating Experience and

    9/24/25 8:30:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Khan Nasser covered exercise/tax liability with 973 shares, decreasing direct ownership by 2% to 55,023 units (SEC Form 4)

    4 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    10/1/25 5:01:03 PM ET
    $ACHC
    Medical Specialities
    Health Care

    New insider Sides Timothy August claimed ownership of 30,661 shares (SEC Form 3)

    3 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    8/25/25 5:01:03 PM ET
    $ACHC
    Medical Specialities
    Health Care

    EVP, GC and Secretary Farley Brian covered exercise/tax liability with 1,095 shares, decreasing direct ownership by 2% to 71,080 units (SEC Form 4)

    4 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    7/29/25 5:01:04 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acadia Healthcare downgraded by BofA Securities with a new price target

    BofA Securities downgraded Acadia Healthcare from Buy to Neutral and set a new price target of $25.00

    9/10/25 7:57:54 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare downgraded by Raymond James with a new price target

    Raymond James downgraded Acadia Healthcare from Strong Buy to Outperform and set a new price target of $26.00

    8/14/25 8:17:37 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare downgraded by Barclays with a new price target

    Barclays downgraded Acadia Healthcare from Overweight to Equal Weight and set a new price target of $35.00 from $43.00 previously

    2/28/25 7:39:54 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    SEC Filings

    View All

    Acadia Healthcare Company Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Acadia Healthcare Company, Inc. (0001520697) (Filer)

    9/29/25 7:05:56 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Acadia Healthcare Company Inc.

    SCHEDULE 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    8/12/25 10:34:26 AM ET
    $ACHC
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Acadia Healthcare Company Inc.

    10-Q - Acadia Healthcare Company, Inc. (0001520697) (Filer)

    8/5/25 4:45:57 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Agave Ridge Behavioral Hospital Hosts Ceremony to Celebrate Grand Opening

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced the opening of its newest acute care hospital, Agave Ridge Behavioral Hospital, located at 3322 S. Ellsworth Road, in Mesa, Arizona. A ribbon-cutting ceremony was held today to mark its grand opening. The first patient admissions are expected to follow in the coming days as the hospital completes its final preparations to provide care for those in need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411986178/en/Acadia Healthcare hosts ribbon-cutting ceremony on April 11, 2024, for its new behavioral health hospital in Mesa, Arizona. The new hospital, named Agave R

    4/11/24 2:16:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced the appointment of Dr. Stephanie Eken as the Company's new chief medical officer. Dr. Eken is a psychiatrist with more than two decades of experience across the spectrum of behavioral health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404108920/en/Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer (Photo: Business Wire) "Acadia is thrilled to welcome Dr. Eken as our new chief medical officer," said Chris Hunter, Chief Executive Officer of Acadia Healthcare. "Her experience and expertise will help Acadia set the standard for care across the i

    4/4/24 9:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Financials

    Live finance-specific insights

    View All

    Acadia Healthcare Reports Second Quarter 2025 Results

    Provides Updated Guidance for 2025; Announces Chief Financial Officer Transition Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Revenue totaled $869.2 million, an increase of 9.2% over the second quarter of 2024 Same facility revenue increased 9.5% compared with the second quarter of 2024, including an increase in revenue per patient day of 7.5% and an increase in patient days of 1.8% Net income attributable to Acadia totaled $30.1 million, or $0.33 per diluted share Adjusted income attributable to Acadia totaled $74.8 million, or $0.83 per

    8/5/25 4:05:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Announces Date for Second Quarter 2025 Earnings Release

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it will release its second quarter 2025 results on Tuesday, August 5, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Wednesday, August 6, 2025. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2025, Acadia operated a network of 270 behavioral healthcare facilities

    7/18/25 11:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Reports First Quarter 2025 Results

    Affirms Full Year 2025 Guidance Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Revenue totaled $770.5 million, compared with $768.1 million for the first quarter of 2024 Same facility revenue increased 2.1% compared with the first quarter of 2024, including an increase in patient days of 2.2% Same facility revenue and patient day growth both included an unfavorable year-over-year impact from the leap year of approximately 1.1% Net income attributable to Acadia totaled $8.4 million, or $0.09 per diluted share Adjusted income attributable to Acadia

    5/12/25 4:07:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/14/24 1:28:32 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/12/24 9:50:14 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/8/24 10:52:39 AM ET
    $ACHC
    Medical Specialities
    Health Care